PARP1 and cancer: In the clinic, patients with a BRCA1 or BRCA2 mutation derive a significant benefit from PARP inhibitor treatment, a finding which has been confirmed in dozens of clinical trials across multiple cancer types including ovarian, breast and prostate cancers [1, 2, 3].